KNOXVILLE, Tenn., Dec. 14 /PRNewswire/ -- Embarrassing and sometimes uncomfortable colonoscopies may soon be a thing of the past. National researchers are taking note of a new screening test that is making its way through the approval process. The Knoxville-based company, EDP Biotech Corporation (EDP) is pursuing a patent for the revolutionary, ColoMarker, an affordable medical device doctors can use to screen for colon cancer with only a blood sample. "When you consider that 30% of colon cancer deaths are avoidable by early screening, the need for a product like ColoMarker is there," says Kevin Jones, Ph.D., Chief Scientific Officer of EDP.
National researchers who study colorectal cancer are closely monitoring emerging technologies, like ColoMarker. Their findings are encouraging; just last week, the Cancer Society, the National Cancer Institute, the Centers for Disease Control and Prevention and the North American Association of Central Cancer Registries released an optimistic report about the expected decline in deaths from colon cancer.
According to the study, the prediction is based on emerging methods for better screening and treatment. The scientists at EDP Biotech say that ColoMarker, screening statistics could soar and the numbers of deaths from colon cancer could plummet. "ColoMarker could lead to a radical shift in the way we detect and treat colon cancer," says Jones.
In tests of 2,370 blood samples, ColoMarker showed an overall accuracy rate for detecting colon cancer of 93%. In another early trial, researchers tested for the presence of ColoMarker in 243 blood samples from patients who had symptoms of colon cancer. They compared the results of these blood tests to results from the Fecal Occult Blood Test (FOBT). ColoMarker had a false positive rate of 11% compared with a false positive rate of 30% for FOBT. This means that ColoMarker is much less likely to identify people as having colon cancer, when they do not have the disease. In this same group of 243 patients, ColoMarker detected 100% of Stage I (early stage) colon cancers, while FOBT identified only about 40% of early stage disease.
The patenting process for ColoMarker is underway and Jones says the company is preparing for clinical trials in the Federal Drug and Administration regulatory approval process. Jones is confident that ColoMarker could save billions of dollars in healthcare costs, but more importantly he says, "We want to move expeditiously to get ColoMarker approved so we can be apart of saving tens of thousands of lives." For more information on the ColoMarker, visit EDP's website at www.edpbiotech.com.
About EDP Biotech Corporation
EDP Biotech Corporation (EDP) is a medical device company focused on the development and sale of immunodiagnostic tests for both humans and animals. EDP utilizes more than 30 years of research and development in identification and purification of proteins present in the early stages of biological changes for production of in vitro diagnostic tests whose primary target is Early Detection Products.
SOURCE EDP Biotech Corporation
|SOURCE EDP Biotech Corporation|
Copyright©2009 PR Newswire.
All rights reserved